SCHEMBL830754

SCHEMBL830754

O=C(Nc1ccc2ccccc2c1Cl)N1CCN(c2ccc(Cl)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.62
ALDH1A1 P00352 6/20 0.62
HSD17B10 Q99714 5/20 0.62
POLB P06746 1/20 0.62
PKM P14618 1/20 0.61
CA12 O43570 2/20 0.54
CA2 P00918 2/20 0.54
CA9 Q16790 2/20 0.54
RBP4 P02753 1/20 0.52
LMNA P02545 5/20 0.51
MAPT P10636 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
HCAR2 Q8TDS4 1/20 0.51
TP53 P04637 1/20 0.51
KMT2A Q03164 1/20 0.50
TRPV1 Q8NER1 1/20 0.50
TSHR P16473 1/20 0.49
NPSR1 Q6W5P4 1/20 0.48
NAMPT P43490 1/20 0.48
USP2 O75604 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830412 0.93 KDM4E (0.73) KDM4EALDH1A1HSD17B10POLBPKM
SCHEMBL830087 0.82 LMNA (0.56) KDM4EALDH1A1HSD17B10POLBPKM
SCHEMBL829706 0.78 KDM4E (0.73) KDM4EALDH1A1HSD17B10POLBPKM
SCHEMBL4028254 0.75 TRPV1 (0.63) KDM4EALDH1A1HSD17B10POLBPKM
SCHEMBL13234944 0.75 CA12 (0.89) KDM4EALDH1A1POLBCA12CA2
SCHEMBL13234938 0.74 CA12 (0.77) KDM4EPOLBCA12CA2CA9
SCHEMBL830071 0.74 FAAH (0.68) KDM4EALDH1A1HSD17B10POLBLMNA
SCHEMBL29748656 0.74 ALDH1A1 (0.62) KDM4EALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL829234 0.73 KDM4E (0.57) KDM4EALDH1A1HSD17B10POLBLMNA
SCHEMBL829538 0.73 ALDH1A1 (0.50) KDM4EALDH1A1HSD17B10POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production VEGFA, FLT4, FLT1 KDM4E 358/4885ALDH1A1 936/4885HSD17B10 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.